AstraZeneca’s share price has been hovering around a long-term trend line established since 2017. Historically, each time the price has tested this trend line, it has rebounded sharply, suggesting strong investor confidence.
From 2017 to 2023, the company’s financial performance has been notably robust:
• Revenue doubled from $22B to $45B.
• Pre-tax income tripled from $2.2B to $6.9B.
• Net income doubled from 3B to $6B.
These figures highlight AstraZeneca’s solid operational growth and underscore its healthy longer-term outlook.
From 2017 to 2023, the company’s financial performance has been notably robust:
• Revenue doubled from $22B to $45B.
• Pre-tax income tripled from $2.2B to $6.9B.
• Net income doubled from 3B to $6B.
These figures highlight AstraZeneca’s solid operational growth and underscore its healthy longer-term outlook.
Note
Still on track!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.